Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Net Cash Flow (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Net Cash Flow data on record, last reported at -$89.6 million in Q1 2026.

  • On a quarterly basis, Net Cash Flow fell 628.86% to -$89.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$23.9 million, a 133.58% decrease, with the full-year FY2025 number at $82.7 million, up 74.81% from a year prior.
  • Net Cash Flow reached -$89.6 million in Q1 2026 per IKT's latest filing, down from $101.0 million in the prior quarter.
  • Over the last five years, Net Cash Flow for IKT hit a ceiling of $101.0 million in Q4 2025 and a floor of -$89.6 million in Q1 2026.
  • A 5-year average of $519022.2 and a median of -$2.2 million in 2024 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: skyrocketed 1075.7% in 2024, then plummeted 1716.49% in 2025.
  • Tracing IKT's Net Cash Flow over 5 years: stood at $1.4 million in 2022, then crashed by 504.95% to -$5.7 million in 2023, then surged by 1075.7% to $55.6 million in 2024, then soared by 81.64% to $101.0 million in 2025, then crashed by 188.8% to -$89.6 million in 2026.
  • Business Quant data shows Net Cash Flow for IKT at -$89.6 million in Q1 2026, $101.0 million in Q4 2025, and -$39.5 million in Q3 2025.